BusinessLegalPipelineResearchEventsProducts
Browse All Stories »
FEATURED
FDA OKs Palatin's phase 3 DED trials on melanocortin agonist

FDA OKs Palatin's phase 3 DED trials on melanocortin agonist

Patient enrollment for MELODY-2 and MELODY-3 studies is expected to start Q4 2024.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Check it out

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Videos
Lumenis's OptiPLUS delivers clinically significant results for DED
Lumenis's OptiPLUS delivers clinically significant results for DED
Ophthalmology Tech Forum to showcase groundbreaking industry innovations
Ophthalmology Tech Forum to showcase groundbreaking industry innovations
CooperVision and AOA launch The Myopia Collective
CooperVision and AOA launch The Myopia Collective
Barti introduces AI transcription tech for optometrists
Barti introduces AI transcription tech for optometrists
Watch More
Business
Samsara Vision promotes industry veteran to COO
Samsara Vision promotes industry veteran to COO
Newly-launched Tern Therapeutics acquires ex-REGENXBIO gene therapies
Newly-launched Tern Therapeutics acquires ex-REGENXBIO gene therapies
Advancing Eyecare purchases Eyefficient ophthalmic supplier
Advancing Eyecare purchases Eyefficient ophthalmic supplier
Ocuvex Therapeutics to merge with Visiox Pharmaceuticals
Ocuvex Therapeutics to merge with Visiox Pharmaceuticals
Research
Blood type may determine retinal structures
Blood type may determine retinal structures
Study identifies Vitamin D benefits for dry eye
Study identifies Vitamin D benefits for dry eye
New data supports NovaSight's binocular eye-tracking device for amblyopia control
New data supports NovaSight's binocular eye-tracking device for amblyopia control
Do ocular allergies negate impact of pediatric ortho-k?
Do ocular allergies negate impact of pediatric ortho-k?
Pipeline
FDA OKs Palatin's phase 3 DED trials on melanocortin agonist
FDA OKs Palatin's phase 3 DED trials on melanocortin agonist
Ciliatech reports positive 36-month follow-up on glaucoma surgical implant
Ciliatech reports positive 36-month follow-up on glaucoma surgical implant
Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution
Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution
FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy
FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy
Products
Oculus adds dual testing to Easyfield VR perimetry device
Oculus adds dual testing to Easyfield VR perimetry device
Bruder to rebrand and distribute Retaine MGD eye drop in the US
Bruder to rebrand and distribute Retaine MGD eye drop in the US
Alcon program guides clinical practices on advanced technology
Alcon program guides clinical practices on advanced technology
Rayner to introduce AI-designed spiral IOL
Rayner to introduce AI-designed spiral IOL
Legal
FTC supports proposed FDA interchangeable biosimilar drug guidance
FTC supports proposed FDA interchangeable biosimilar drug guidance
LumiThera receives first CPT code for retina-based PBM therapy
LumiThera receives first CPT code for retina-based PBM therapy
Optometry excluded in new DC scope of practice legislation
Optometry excluded in new DC scope of practice legislation
FTC adds final compliance-targeted updates to Eyeglass Rule
FTC adds final compliance-targeted updates to Eyeglass Rule
Archives
Hello 2023 — Weekly Glance
Hello 2023 — Weekly Glance
Can we treat uveitis without steroids? — Weekly Glance
Can we treat uveitis without steroids? — Weekly Glance
Can I have one dilation drop instead of two? — Weekly Glance
Can I have one dilation drop instead of two? — Weekly Glance
Are those dilation reversal drops available yet? — Weekly Glance
Are those dilation reversal drops available yet? — Weekly Glance
Events
AOA launches educational prototype for eye health awareness campaign
AOA launches educational prototype for eye health awareness campaign
KOLs eye the future of genetic engineering and cell transplantation
KOLs eye the future of genetic engineering and cell transplantation
ASCRS launches AT IOL-focused educational initiative
ASCRS launches AT IOL-focused educational initiative
Data is the future of ophthalmic patient care, industry leader says
Data is the future of ophthalmic patient care, industry leader says
Browse All Stories »